Genetic Analysis AS (XSAT:GEAN)

Market Cap	44.30M -28.7%
Revenue (ttm)	21.06M +8.1%
Net Income	-11.17M
EPS	-0.17
Shares Out	69.09M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,838
Open	0.6800
Previous Close	0.6500
Day's Range	0.6400 - 0.6800
52-Week Range	0.5560 - 1.1000
Beta	2.08
Analysts	n/a
Price Target	3.50 (+446.88%)
Earnings Date	May 28, 2026

About Genetic Analysis AS

Genetic Analysis AS, a science-based diagnostic company, engages in the research, development, manufacturing, and sale of diagnostic test solutions for human microbiome in the United States, Europe, and internationally. The company offers GA-map MHI Gut Health Test, a microbiome-based diagnostic test for antibiotic-induced microbiome imbalances; GA-map Dysbiosis Test, a diagnostic microbiome test that detects and characterizes dysbiosis; GA-map Discovery, a microbiome research assay; GA-map Sample Collection Kit for the collection, transport, a...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2008
• Employees: 18
• Stock Exchange: Spotlight Stock Market
• Ticker Symbol: GEAN

Financial Performance

In 2025, Genetic Analysis AS's revenue was 21.17 million, an increase of 2.36% compared to the previous year's 20.68 million. Losses were -11.41 million, -22.72% less than in 2024.

Financial numbers in NOK